🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Syngenta, Ginkgo Bioworks join forces for ag biologicals

EditorIsmeta Mujdragic
Published 07/16/2024, 11:08 AM
DNA
-

BASEL, Switzerland - Syngenta Crop Protection and Ginkgo Bioworks announced a partnership aimed at expediting the development and commercialization of a new biological solution for agriculture. The collaboration, announced today, will focus on optimizing the production of a specific secondary metabolite identified by Syngenta as a key component in its biologicals pipeline.

The partnership leverages Ginkgo's expertise in microbial strain development and its Ag Biologicals capabilities to meet Syngenta's productivity targets for the metabolite. By applying machine learning and data analysis, Ginkgo aims to develop a robust microbial strain capable of cost-effective, large-scale production, which is crucial for the timely release of Syngenta's product.

Camilla Corsi, Global Head of Research at Syngenta Crop Protection, highlighted the growing importance of biologicals in sustainable agriculture and expressed confidence in Ginkgo's capabilities to meet their productivity goals. Magalie Guilhabert, Head of Ag Biologicals at Ginkgo Bioworks, also emphasized the expansion of their successful relationship with Syngenta and the commitment to overcoming challenges in the ag biologicals sector.

The announcement follows previous collaborations between the two companies on next-generation seed technologies. This new venture is expected to contribute to the broader efforts of providing sustainable agricultural solutions to farmers worldwide.

Syngenta, headquartered in Basel, Switzerland, is known for its innovative crop protection solutions and services, while Boston-based Ginkgo Bioworks specializes in cell programming and biosecurity across various industries.

The information in this article is based on a press release.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.